Guillain-Barre Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink

Importance: Post-authorization monitoring of vaccines in a large population can detect rare adverse events not identified in clinical trials including Guillain-Barre syndrome (GBS). GBS has a background rate of 1-2 per 100,000 person-years. Objective: To 1) describe cases and incidence of GBS following COVID-19 vaccination, and 2) assess the risk of GBS after vaccination for Ad.26.COV2.S (Janssen) and mRNA vaccines. Design: Interim analysis of surveillance data from the Vaccine Safety Datalink. Setting: Eight participating integrated healthcare systems in the United States. Participants: 10,158,003 individuals aged [≥]12 years. Exposures: Receipt of Ad.26.COV2.S, BNT162b2 (Pfizer-BioNTech), or mRNA-1273 (Moderna) COVID-19 vaccine. Main Outcomes and Measures: GBS with symptom onset in the 1-84 days after vaccination as confirmed by medical record review and adjudication. Descriptive characteristics of confirmed cases, GBS incidence rates during postvaccination risk intervals after each type of vaccine compared to the background rate, rate ratios (RRs) comparing GBS incidence in the 1-21 vs. 22-42 days postvaccination, and RRs directly comparing risk of GBS after Ad.26.COV2.S vs. mRNA vaccination, using Poisson regression adjusted for age, sex, race/ethnicity, site, and calendar day. Results: From December 13, 2020 through November 13, 2021, 14,723,318 doses of COVID-19 vaccines were administered, including 467,126 Ad.26.COV2.S, 8,573,823 BNT162b2, and 5,682,369 mRNA-1273 doses. Eleven cases of GBS after Ad.26.COV2.S were confirmed. The unadjusted incidence rate of confirmed cases of GBS per 100,000 person-years in the 1-21 days after Ad.26.COV2.S was 34.6 (95% confidence interval [CI]: 15.8-65.7), significantly higher than the background rate, and the adjusted RR in the 1-21 vs. 22-42 days following Ad.26.COV2.S was 6.03 (95% CI: 0.79-147.79). Thirty-four cases of GBS after mRNA vaccines were confirmed. The unadjusted incidence rate of confirmed cases per 100,000 person-years in the 1-21 days after mRNA vaccines was 1.4 (95% CI: 0.7-2.5) and the adjusted RR in the 1-21 vs. 22-42 days following mRNA vaccines was 0.56 (95% CI: 0.21-1.48). In a head-to-head comparison of Ad.26.COV2.S vs. mRNA vaccines, the adjusted RR was 20.56 (95% CI: 6.94-64.66). Conclusions and Relevance: In this interim analysis of surveillance data of COVID-19 vaccines, the incidence of GBS was elevated after Ad.26.COV2.S. Surveillance is ongoing.

[1]  B. Bell,et al.  Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  M. Lunn,et al.  COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  OUP accepted manuscript , 2022, Brain.

[4]  Joshua T. B. Williams,et al.  Monitoring vaccine safety using the vaccine safety Datalink: Assessing capacity to integrate data from Immunization Information systems , 2021, Vaccine.

[5]  E. Woo,et al.  Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. , 2021, JAMA.

[6]  J. Gargano,et al.  Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[7]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[8]  Medha Tandon,et al.  A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination , 2021, Neurology international.

[9]  E. Woo,et al.  Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[10]  Esha Jain,et al.  Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine , 2021, Cureus.

[11]  P. Tighe,et al.  Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination , 2021, Annals of neurology.

[12]  H. Mangat,et al.  Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine , 2021, Annals of neurology.

[13]  J. Gargano,et al.  Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[14]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[15]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[16]  S. Sheikh,et al.  Guillain-Barré Syndrome Incidence in a Large United States Cohort (2000–2009) , 2012, Neuroepidemiology.

[17]  Ruihua Yin,et al.  H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. , 2011, American journal of preventive medicine.

[18]  Steven J. Jacobsen,et al.  The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety , 2011, Pediatrics.

[19]  Matthew Wise,et al.  Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[20]  J. Sejvar,et al.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[21]  B. Jacobs,et al.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome , 2008, The Lancet Neurology.

[22]  B. Pernici.  Monitoring , 2008, Encyclopedia of GIS.

[23]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[24]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[25]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[26]  M Kulldorff,et al.  Spatial disease clusters: detection and inference. , 1995, Statistics in medicine.